Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type

Observational

Phase

Not applicable / not listed

Age range

Not specified - 25 years

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

150 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The goal of this study is to better understand biological characteristics of non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), a rare group of cancers that affect children, adolescents, and young adults. Researchers also aim to identify factors that could help predict how the disease will behave and respond to treatment.

The main questions it aims to answer are:

• Can advanced molecular analyses improve the classification and diagnosis of NRSTS?
• Can blood- and tumor-based biomarkers help predict outcomes and detect relapse earlier?
• Can researchers identify biological features that may guide future personalized treatments?

Participants aged 0 to 25 years with a recent diagnosis of NRSTS will take part in the prospective study. Researchers will collect archived tumor samples and blood samples during routine follow-up (approximately every 3 to 4 months) and will analyze these samples using advanced laboratory techniques. Clinical information will also be collected over a follow-up period of up to 4 years.

150 participants will be enrolled in the prospective part from 28 investigating centers across France.

Tumor samples already collected as part of your care, together with blood samples taken during follow-up visits, will be stored for future researches.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

1. Patients with local diagnosis of intermediate or malignant NRSTS, at the time of initial diagnosis only.
2. Localized or metastatic disease.
3. Age: 0-25 years.
4. Whatever strategy is decided (observation, surgery, chemotherapy, radiotherapy, other systemic therapies).
5. Within the 3 months after initial diagnosis.
6. Written informed consent from adult patients, or the 2 parents/legal representatives. Assent from minor patients should be verified.
7. Availability of archived tissue samples. Adult participants or parents must be willing to provide archival tissue. A minimum of 1 FFPE block / 1 HE slide with IHC slides available is required.
8. Patient affiliated to a health insurance system.

Exclusion Criteria:

1. NRSTS at relapse.
2. Any significant medical, psychological, social or geographic conditions that, in the opinion of the Investigator, would impair study participation or cooperation.
3. Patients deprived of their liberty or under guardianship.

Study population

Children and young adults (aged from 0 to 25 years) with a new diagnosis of NRSTS.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not reported

Masking

Not reported

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Research locations (28)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

28 locations

Study team and timeline

Lead sponsor

Institut Curie

Study start

2026-12 Estimated

Primary completion

2034-12 Estimated

Study completion

2034-12 Estimated

First posted

Nov 9, 2026 Actual

Last updated

Nov 9, 2026 Actual

Official study contacts